Brokerages Anticipate ADMA Biologics Inc (NASDAQ:ADMA) Will Announce Earnings of -$0.20 Per Share

Wall Street brokerages expect that ADMA Biologics Inc (NASDAQ:ADMA) will post earnings per share (EPS) of ($0.20) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for ADMA Biologics’ earnings. The lowest EPS estimate is ($0.22) and the highest is ($0.18). ADMA Biologics reported earnings per share of ($0.39) during the same quarter last year, which would suggest a positive year-over-year growth rate of 48.7%. The company is expected to report its next quarterly earnings report on Wednesday, March 11th.

On average, analysts expect that ADMA Biologics will report full-year earnings of ($0.92) per share for the current financial year, with EPS estimates ranging from ($0.94) to ($0.89). For the next year, analysts expect that the firm will post earnings of ($0.81) per share, with EPS estimates ranging from ($1.44) to ($0.37). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that cover ADMA Biologics.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.04. ADMA Biologics had a negative return on equity of 203.21% and a negative net margin of 260.92%. The firm had revenue of $7.22 million for the quarter, compared to analyst estimates of $5.71 million.

Several analysts have weighed in on ADMA shares. Maxim Group set a $12.00 price objective on ADMA Biologics and gave the company a “buy” rating in a research report on Monday, October 21st. ValuEngine lowered ADMA Biologics from a “hold” rating to a “sell” rating in a research note on Friday. HC Wainwright restated a “buy” rating on shares of ADMA Biologics in a research note on Wednesday, January 8th. Finally, BidaskClub raised shares of ADMA Biologics from a “strong sell” rating to a “sell” rating in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. ADMA Biologics has a consensus rating of “Hold” and a consensus target price of $10.20.

Several institutional investors have recently bought and sold shares of ADMA. Parametric Portfolio Associates LLC acquired a new position in shares of ADMA Biologics in the 2nd quarter valued at about $49,000. Tower Research Capital LLC TRC raised its holdings in shares of ADMA Biologics by 13,268.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 13,368 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 13,268 shares in the last quarter. Voya Investment Management LLC raised its holdings in shares of ADMA Biologics by 60.4% in the 3rd quarter. Voya Investment Management LLC now owns 18,688 shares of the biotechnology company’s stock worth $83,000 after purchasing an additional 7,038 shares in the last quarter. Metropolitan Life Insurance Co NY bought a new stake in shares of ADMA Biologics in the 3rd quarter worth approximately $85,000. Finally, Citadel Advisors LLC raised its holdings in shares of ADMA Biologics by 96.3% in the 2nd quarter. Citadel Advisors LLC now owns 22,187 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 10,887 shares in the last quarter. 62.70% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ ADMA traded up $0.06 during midday trading on Thursday, hitting $4.41. 14,416 shares of the company traded hands, compared to its average volume of 806,561. ADMA Biologics has a 12-month low of $2.56 and a 12-month high of $6.31. The firm has a market cap of $267.52 million, a P/E ratio of -3.02 and a beta of 2.58. The stock has a 50-day moving average price of $4.19 and a 200 day moving average price of $4.24. The company has a debt-to-equity ratio of 2.33, a quick ratio of 3.76 and a current ratio of 6.42.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Article: Average Daily Trade Volume – What You Need to Know

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.